ahlam1399
09-02-2015, 12:32 AM
Alexion gets EU approval for drug acquired in Synageva deal
NEW YORK (Reuters) - Ten weeks after closing its $8.4 billion purchase of Synageva BioPharma Corp, Alexion Pharmaceuticals Inc on Tuesday an**unced European approval for the key drug acquired through the deal, an enzyme-replacement therapy for an ultra-rare, life threatening disease.
http://i2.wp.com/reuters.us.feedsportal.com/c/35217/f/654207/s/497bbe80/sc/21/mf.gif?resize=1%2C1http://feeds.feedburner.com/~ff/reuters/healthNews?d=yIl2AUoC8zA (http://feeds.reuters.com/~ff/reuters/healthNews?a=r4pngLm5iYQ:X5jZkeM2muY:yIl2AUoC8zA) http://feeds.feedburner.com/~ff/reuters/healthNews?i=r4pngLm5iYQ:X5jZkeM2muY:F7zBnMyn0Lo (http://feeds.reuters.com/~ff/reuters/healthNews?a=r4pngLm5iYQ:X5jZkeM2muY:F7zBnMyn0Lo) http://feeds.feedburner.com/~ff/reuters/healthNews?i=r4pngLm5iYQ:X5jZkeM2muY:V_sGLiPBpWU (http://feeds.reuters.com/~ff/reuters/healthNews?a=r4pngLm5iYQ:X5jZkeM2muY:V_sGLiPBpWU)
http://feeds.feedburner.com/~r/reuters/healthNews/~4/r4pngLm5iYQ
NEW YORK (Reuters) - Ten weeks after closing its $8.4 billion purchase of Synageva BioPharma Corp, Alexion Pharmaceuticals Inc on Tuesday an**unced European approval for the key drug acquired through the deal, an enzyme-replacement therapy for an ultra-rare, life threatening disease.
http://i2.wp.com/reuters.us.feedsportal.com/c/35217/f/654207/s/497bbe80/sc/21/mf.gif?resize=1%2C1http://feeds.feedburner.com/~ff/reuters/healthNews?d=yIl2AUoC8zA (http://feeds.reuters.com/~ff/reuters/healthNews?a=r4pngLm5iYQ:X5jZkeM2muY:yIl2AUoC8zA) http://feeds.feedburner.com/~ff/reuters/healthNews?i=r4pngLm5iYQ:X5jZkeM2muY:F7zBnMyn0Lo (http://feeds.reuters.com/~ff/reuters/healthNews?a=r4pngLm5iYQ:X5jZkeM2muY:F7zBnMyn0Lo) http://feeds.feedburner.com/~ff/reuters/healthNews?i=r4pngLm5iYQ:X5jZkeM2muY:V_sGLiPBpWU (http://feeds.reuters.com/~ff/reuters/healthNews?a=r4pngLm5iYQ:X5jZkeM2muY:V_sGLiPBpWU)
http://feeds.feedburner.com/~r/reuters/healthNews/~4/r4pngLm5iYQ